Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Merck & Co., Inc. (MRK) Price & Performance

iShares MSCI Taiwan ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Merck & Co., Inc. — how do they compare? iShares MSCI Taiwan ETF trades at $106.13, while Merck & Co., Inc. trades at $130.44 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals.

EWTMRK
Sector
Broad Market / FactorHealth
52-Week High
$111.53$131.84
52-Week Low
$58.05$77.60
Market Cap
$321.77B
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT (iShares MSCI Taiwan ETF) trades at $106.34, up 4.07% with strong bullish momentum. Technical indicators show moving averages strongly bullish while oscillators are neutral. The ETF benefits from Taiwan's AI-driven semiconductor exposure, with TSMC representing 22.5% weighting. Recent news highlights Taiwan's strong 2026 performance driven by AI chip demand, though some rotation from Asian AI winners has occurred.

Outlook remains positive given Taiwan's critical semiconductor role and AI infrastructure demand. Key risks include geopolitical tensions with China, foreign capital outflows, and semiconductor cycle volatility. The ETF's heavy tech concentration provides growth potential but increases sector-specific risk exposure.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK